Bio-Works Technologies EBITDA per Employee
The EBITDA per Employee of Bio-Works Technologies (BIOWKS.SL) as of Oct 11, 2026 is -350,380.00 SEK. In the previous year, EBITDA per Employee was -749,640.00 SEK — a change of -53.26% (higher).
Get this data via API
Financial Data API
EBITDA per Employee
-350,380.00SEK
YoY
-53.26%
Last updated:
The Bio-Works Technologies EBITDA per Employee history
3 Years
10 Years
25 Years
Max
| YEAR | EBITDA per Employee | YoY |
|---|---|---|
| -350,380.00SEK | -53.26% | |
| -749,640.00SEK | -31.61% | |
| -1.10 MSEK | +17.44% | |
| -933,360.00SEK | +355.30% | |
| -205,000.00SEK | -77.20% | |
| -899,080.00SEK | +8.87% | |
| -825,860.00SEK | +32.32% | |
| -624,140.00SEK | +46.20% | |
| -426,920.00SEK | +41.50% | |
| -301,700.00SEK | +30.34% | |
| -231,480.00SEK | — |
Bio-Works Technologies Stock analysis
Frequently Asked Questions about Bio-Works Technologies stock
EBITDA per Employee of Bio-Works Technologies is -350,380.00 SEK in 2025.
EBITDA per Employee of Bio-Works Technologies changed from -749,640.00 SEK to -350,380.00 SEK, representing a -53.26% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBITDA per Employee Bio-Works Technologies since 2006 – with annual values, charts, and detailed analysis.
EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.
EBITDA per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Bio-Works Technologies historically and in real time.
Workforce — Bio-Works Technologies
All Key Metrics — Bio-Works Technologies
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth